Several factors contribute to the development of arthritis in athletes. The most significant cause is repetitive joint stress, osteoarthritis, the most common form of arthritis among athletes.
UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...